Compliance packaging to benefit from healthcare reform

Packaging that promotes patient compliance with drug regimens may be one area that gets additional attention as a result of healthcare reform. Further development and use of such packaging will, of course, be another driver of drug costs, but it may net a decrease in the overall cost of healthcare.

Use of compliance packaging may in particular grow for cold chain products, says one respondent to a late-September survey by Healthcare Packaging. Another cites clinical trials: "Our customers are usually willing to pay more for compliance packaging features if they are crucial to the particular study."

One survey-taker expresses concern that compliance features could impact the sterility and  integrity of drug products.

- see the article

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.